Table 4

Follow up of patients injected with placebo

Patient number

Age (years)

Date of surgery

Type of treatment

Tumour size (cm)

Total nodes

Metastatic nodes

Grade

Date of first injection

Side effects

Recurrence

Last follow up

Follow up (months)

17

62

11/12/97

Total mast + tam

2.5

27

1

II

28/01/98

Mild skin redness

-

14/06/05

99

18

54

14/12/97

Partial mast + RT + tam

2.0

20

1

II

10/01/98

-

Local, 14/07/99

14/06/05

99

19

55

16/12/97

Partial mast + RT + tam

1.5

17

1

II

06/05/98

-

-

14/06/05

99

20

60

23/12/97

Partial mast + RT + tam

2.3

24

2

II

13/12/97

-

-

16/06/05

99

21

62

20/01/98

Total mast + tam

2.4

27

2

II

13/03/98

-

-

16/06/05

98

22

61

13/03/98

Total mast + tam

1.8

23

2

I

29/04/98

-

-

17/06/05

97

23

62

01/04/98

Partial mast + RT + tam

1.5

12

1

II

08/07/98

Mild skin redness

-

17/06/05

96

24

54

29/04/98

Partial mast + RT + tam

0.5

17

1

III

22/07/98

Mild skin redness

-

21/06/05

96

25

58

10/11/98

Total mast + tam

2.2

21

3

II

30/01/98

-

Bone, 13/11/00

Death 10/11/03

26

51

17/02/99

Partial mast + RT + tam

2.0

11

1

II

10/03/99

-

Bone, 28/09/00

21/06/05

86

27

71

10/06/99

Total mast + tam

3.2

26

1

II

01/07/99

-

-

23/06/05

82

28

70

30/06/99

Partial mast + RT + tam

2.0

20

3

II

13/07/99

-

-

23/06/05

82

29

54

02/12/99

Partial mast + RT + tam

2.5

12

1

II

10/01/00

-

-

24/06/05

76

30

81

08/12/99

Total mast + tam

2.5

14

1

III

10/01/00

-

-

27/06/05

75

31

58

24/02/00

Partial mast + RT + tam

2.0

13

3

II

20/03/00

Mild skin redness

Liver, 16/11/00

Death 2002

mast, mastectomy; M-FP, oxidized mannan conjugated to MUC1 fusion protein; RT, radiotherapy; tam, tamoxifen.

Apostolopoulos et al. Breast Cancer Research 2006 8:R27   doi:10.1186/bcr1505